ASH 2023 | The BOVen trial: MRD-guided obinutuzumab, zanubrutinib and venetoclax regimen in TP53-mutated MCL
Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the BOVen trial (NCT03824483), investigating MRD-directed treatment with obinutuzumab (anti-CD20 antibody), zanubrutinib (BTK inhibitor) and venetoclax (BCL2 inhibitor) in patients with previously untreated TP53-mutated mantle cell lymphoma (MCL). After a median follow-up of 16 months, this triplet regimen was well-tolerated with deep responses, including a complete remission (CR) rate of 88% and 1-year progression-free survival (PFS) of 84%. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Beigene, Abbvie, Eli Lilly and Company, Incyte, Autolus, Janssen, KITE, Loxo Oncology, AstraZeneca, Roche, Gilead
Honoraria: Beigene, Abbvie, Eli Lilly and Company, Janssen, KITE, Loxo Oncology, AstraZeneca, Roche, Gilead
Membership on Board of Directors/Advisory Committee: Beigene, Abbvie, Incyte, KITE, AstraZeneca, Roche, Gilead, Loxo Lilly
Research Funding: Beigene, AstraZeneca, Secura Bio
Speakers Bureau: Beigene, Abbvie, Eli Lilly and Company, Incyte, Janssen, KITE, Loxo Oncology, AstraZeneca, Roche, Gilead, Loxo Lilly, PeerView, Medscape
Other: Loxo Oncology
